Objectives: To provide guidance for the management of mood disorders, based on scientific
evidence supplemented by expert clinical consensus and formulate recommendations to …

Newer generation antidepressant drugs (ADs) are widely used as the first line of treatment
for major depressive disorders and are considered to be safer than tricyclic agents. In this …

Depression is a common complication of pregnancy and the postpartum period. There are
multiple risk factors for peripartum mood disorders, most important of which is a prior history …

Postpartum depression (PPD) affects up to 15% of mothers. Recent research has identified
several psychosocial and biologic risk factors for PPD. The negative short-term and long …

Depression is a widespread condition affecting approximately 7.5 million parents in the US
each year and may be putting at least 15 million children at risk for adverse health …

Drug-protein binding plays a key role in determining the pharmacokinetics of a drug. The
distribution and protein binding ability of a drug changes over a lifetime, and are important …

Postpartum depression (PPD) is a unique subtype of major depressive disorder and a
substantial contributor to maternal morbidity and mortality. In addition to affecting the mother …

Postpartum depression (PPD) is a common complication of childbearing, and has
increasingly been identified as a major public health problem. Untreated maternal …

Maternal perinatal mental health has enormous consequences for the well-being of the
mother, her baby, and the family. Although it is well documented that perinatal depression is …

BACKGROUND: In 2001, the Canadian Psychiatric Association and the Canadian Network
for Mood and Anxiety Treatments (CANMAT) partnered to produce evidence-based clinical …